Translational Pharmacology
for Oncology, Inflammation and
Radiopharmaceutical Innovation

Working with Oncodesign Services has been a true drug development partnership – delivering great results over a period of years.​ As an early-stage company, we needed a partner both we and our investors could trust to deliver on time and on budget as part of our regulatory submissions. Oncodesign’s oncology expertise and ability to bring together in vitro and in vivo work under one roof gave us that confidence from the outset.

ODS does exactly what it says it will do, on time and on budget, which is critical for a small company like ours.

Oncodesign Services (ODS) has been a trusted preclinical partner for several years. The team consistently demonstrates scientific excellence and reliability, tailoring preclinical protocols to our exact needs.
Their ability to rapidly action and deliver projects has made collaboration in oncology research efficient and straightforward. Clear, responsive communication is crucial to us, and the strong working relationship with our client manager makes coordination very easy.
We appreciate the professionalism, confidence, and flexibility ODS brings to every project.

We partnered with the Oncodesign Services team to support the development of a targeted radiotherapy agent, with the goal of confirming in vivo activity across multiple tumor models and directly comparing candidate compounds.
Their radiopharmaceutical expertise was invaluable, particularly in guiding radionuclide comparison of beta vs alpha emitters and dosing strategies.
Throughout the project, we appreciated the ODS team’s commitment to timelines and transparent communication. Our partnership was well professionally managed through regular open scientific exchanges and a foundation of trust and collaboration.